Baidu
map

药物研发史上里程碑式的进展——科学家可无限制的生产功能性肝细胞

2015-08-02 sunshine 译 MedSci原创

肝脏在人体代谢过程中起着重要的作用。作为消化道的“门卫”,肝脏负责药物的降解,因此成为了最易由于药物过量或滥用而受损的器官。评估药物诱导性肝损伤是研发药物的重要部分,必须对人体干细胞进行研究实验。遗憾的是,人类干细胞的供应很少,仅能从捐赠的器官中分离获得。现在,发表于《肝脏病学杂志 》的一项研究表明,科学家已成功通过人胚胎干细胞和基因功能诱导出大量有功能的肝细胞。“这是药物研发史上一个革


肝脏在人体代谢过程中起着重要的作用。作为消化道的“门卫”,肝脏负责药物的降解,因此成为了最易由于药物过量或滥用而受损的器官。评估药物诱导性肝损伤是研发药物的重要部分,必须对人体干细胞进行研究实验。遗憾的是,人类干细胞的供应很少,仅能从捐赠的器官中分离获得。

现在,发表于《肝脏病学杂志 》的一项研究表明,科学家已成功通过人胚胎干细胞和基因功能诱导出大量有功能的肝细胞。

“这是药物研发史上一个革命性的进展,”本研究资深作者 Prof. Yaakov Nahmias说道,“虽然在我们之前也有研究人员可诱导出肝细胞,但是他们所诱导出的肝细胞并没有功能活性,因此用于研究效果并不可靠。事实上,到目前为止,干细胞来源的肝细胞在预测临川结果方面并无作用。”

诱导出有功能的肝细胞是药物试验中遇到的一个主要瓶颈,制药公司每年仅在肝细胞研究上花费便可达10亿美金。“我们可无限制的生产功能性肝细胞这一能力将彻底改变这一切,”Nahmias说道。

这一突破是随着今年早些时候女婴Nahmias的出生而来。“看着她出生后片刻后进食,我意识到这是她的肝脏首次开始工作,”Nahmias说道,“以前从未有人想过模仿人类的发育,所以这正是我们所做的。”

该研究小组接着发现出生后细菌填充了婴儿的肠道,产生维生素K2和胆酸,可激活婴儿肝脏的药物代谢功能。

这项开创性工作进一步证实了,胚胎干细胞或基因工程所产生的肝细胞均可检测十几种药物的毒副作用,其准确率达97%以上。

“肝脏生物学及药物研发的影响是相当惊人的,” Prof. Oren Shibolet说道,“这种方法可无限制的产生功能性肝细胞,可提高我们预测药物毒性的能力,而这时以往所生产的肝细胞所不能做到的。此外,由于剖腹产婴儿的肠道菌群发生了变化,因此分娩的方式可能会影响新生儿肝脏的发育。目前的应对措施是给予婴儿常规服用维生素C。研究数据表明,父母若不给予婴儿维生素C,则可能导致婴儿肝脏的发育成熟及药物的代谢发生改变。”

原始出处:

Avior Y, Levy G, Zimerman M, Kitsberg D, Schwartz R, Sadeh R, Moussaieff A, Cohen M, Itskovitz-Eldor J, Nahmias Y.Microbial-derived lithocholic acid and vitamin K2 drive the metabolic maturation of pluripotent stem cells-derived and fetal hepatocytes.Hepatology. 2015 Jul;62(1):265-78.


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1915396, encodeId=c4b01915396ca, content=<a href='/topic/show?id=22a1328e7e5' target=_blank style='color:#2F92EE;'>#功能性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32877, encryptionId=22a1328e7e5, topicName=功能性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Jul 01 13:11:00 CST 2016, time=2016-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059268, encodeId=ccdb205926861, content=<a href='/topic/show?id=9fbe95e0015' target=_blank style='color:#2F92EE;'>#里程碑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95700, encryptionId=9fbe95e0015, topicName=里程碑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Tue Jun 14 12:11:00 CST 2016, time=2016-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863238, encodeId=99c41863238c4, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Fri Nov 13 19:11:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299884, encodeId=21f0129988406, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Tue Aug 04 02:11:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301424, encodeId=304113014241b, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Tue Aug 04 02:11:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517695, encodeId=6afe151e695ad, content=<a href='/topic/show?id=44156886664' target=_blank style='color:#2F92EE;'>#生产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68866, encryptionId=44156886664, topicName=生产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37a111112788, createdName=ms1343860338762272, createdTime=Tue Aug 04 02:11:00 CST 2015, time=2015-08-04, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1915396, encodeId=c4b01915396ca, content=<a href='/topic/show?id=22a1328e7e5' target=_blank style='color:#2F92EE;'>#功能性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32877, encryptionId=22a1328e7e5, topicName=功能性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Jul 01 13:11:00 CST 2016, time=2016-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059268, encodeId=ccdb205926861, content=<a href='/topic/show?id=9fbe95e0015' target=_blank style='color:#2F92EE;'>#里程碑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95700, encryptionId=9fbe95e0015, topicName=里程碑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Tue Jun 14 12:11:00 CST 2016, time=2016-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863238, encodeId=99c41863238c4, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Fri Nov 13 19:11:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299884, encodeId=21f0129988406, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Tue Aug 04 02:11:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301424, encodeId=304113014241b, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Tue Aug 04 02:11:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517695, encodeId=6afe151e695ad, content=<a href='/topic/show?id=44156886664' target=_blank style='color:#2F92EE;'>#生产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68866, encryptionId=44156886664, topicName=生产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37a111112788, createdName=ms1343860338762272, createdTime=Tue Aug 04 02:11:00 CST 2015, time=2015-08-04, status=1, ipAttribution=)]
    2016-06-14 xzw113
  3. [GetPortalCommentsPageByObjectIdResponse(id=1915396, encodeId=c4b01915396ca, content=<a href='/topic/show?id=22a1328e7e5' target=_blank style='color:#2F92EE;'>#功能性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32877, encryptionId=22a1328e7e5, topicName=功能性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Jul 01 13:11:00 CST 2016, time=2016-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059268, encodeId=ccdb205926861, content=<a href='/topic/show?id=9fbe95e0015' target=_blank style='color:#2F92EE;'>#里程碑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95700, encryptionId=9fbe95e0015, topicName=里程碑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Tue Jun 14 12:11:00 CST 2016, time=2016-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863238, encodeId=99c41863238c4, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Fri Nov 13 19:11:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299884, encodeId=21f0129988406, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Tue Aug 04 02:11:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301424, encodeId=304113014241b, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Tue Aug 04 02:11:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517695, encodeId=6afe151e695ad, content=<a href='/topic/show?id=44156886664' target=_blank style='color:#2F92EE;'>#生产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68866, encryptionId=44156886664, topicName=生产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37a111112788, createdName=ms1343860338762272, createdTime=Tue Aug 04 02:11:00 CST 2015, time=2015-08-04, status=1, ipAttribution=)]
    2015-11-13 xjy02
  4. [GetPortalCommentsPageByObjectIdResponse(id=1915396, encodeId=c4b01915396ca, content=<a href='/topic/show?id=22a1328e7e5' target=_blank style='color:#2F92EE;'>#功能性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32877, encryptionId=22a1328e7e5, topicName=功能性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Jul 01 13:11:00 CST 2016, time=2016-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059268, encodeId=ccdb205926861, content=<a href='/topic/show?id=9fbe95e0015' target=_blank style='color:#2F92EE;'>#里程碑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95700, encryptionId=9fbe95e0015, topicName=里程碑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Tue Jun 14 12:11:00 CST 2016, time=2016-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863238, encodeId=99c41863238c4, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Fri Nov 13 19:11:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299884, encodeId=21f0129988406, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Tue Aug 04 02:11:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301424, encodeId=304113014241b, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Tue Aug 04 02:11:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517695, encodeId=6afe151e695ad, content=<a href='/topic/show?id=44156886664' target=_blank style='color:#2F92EE;'>#生产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68866, encryptionId=44156886664, topicName=生产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37a111112788, createdName=ms1343860338762272, createdTime=Tue Aug 04 02:11:00 CST 2015, time=2015-08-04, status=1, ipAttribution=)]
    2015-08-04 lqvr
  5. [GetPortalCommentsPageByObjectIdResponse(id=1915396, encodeId=c4b01915396ca, content=<a href='/topic/show?id=22a1328e7e5' target=_blank style='color:#2F92EE;'>#功能性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32877, encryptionId=22a1328e7e5, topicName=功能性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Jul 01 13:11:00 CST 2016, time=2016-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059268, encodeId=ccdb205926861, content=<a href='/topic/show?id=9fbe95e0015' target=_blank style='color:#2F92EE;'>#里程碑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95700, encryptionId=9fbe95e0015, topicName=里程碑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Tue Jun 14 12:11:00 CST 2016, time=2016-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863238, encodeId=99c41863238c4, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Fri Nov 13 19:11:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299884, encodeId=21f0129988406, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Tue Aug 04 02:11:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301424, encodeId=304113014241b, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Tue Aug 04 02:11:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517695, encodeId=6afe151e695ad, content=<a href='/topic/show?id=44156886664' target=_blank style='color:#2F92EE;'>#生产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68866, encryptionId=44156886664, topicName=生产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37a111112788, createdName=ms1343860338762272, createdTime=Tue Aug 04 02:11:00 CST 2015, time=2015-08-04, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1915396, encodeId=c4b01915396ca, content=<a href='/topic/show?id=22a1328e7e5' target=_blank style='color:#2F92EE;'>#功能性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32877, encryptionId=22a1328e7e5, topicName=功能性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Jul 01 13:11:00 CST 2016, time=2016-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059268, encodeId=ccdb205926861, content=<a href='/topic/show?id=9fbe95e0015' target=_blank style='color:#2F92EE;'>#里程碑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95700, encryptionId=9fbe95e0015, topicName=里程碑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Tue Jun 14 12:11:00 CST 2016, time=2016-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863238, encodeId=99c41863238c4, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Fri Nov 13 19:11:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299884, encodeId=21f0129988406, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Tue Aug 04 02:11:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301424, encodeId=304113014241b, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Tue Aug 04 02:11:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517695, encodeId=6afe151e695ad, content=<a href='/topic/show?id=44156886664' target=_blank style='color:#2F92EE;'>#生产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68866, encryptionId=44156886664, topicName=生产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37a111112788, createdName=ms1343860338762272, createdTime=Tue Aug 04 02:11:00 CST 2015, time=2015-08-04, status=1, ipAttribution=)]

相关资讯

Science:药物研发新革命

科学家们用冷冻电镜(cryo-EM)成像了代谢酶与其抑制剂的结合,获得了空前的高分辨率。他们认为,这种技术将为药物研发带来一场革命。了解一个酶与药物结合时的精确结构,就可以更好的设计药物来阻断或者增强酶的活性。美国国立癌症研究所NCI(隶属NIH)的Sriram Subramaniam博士领导研究团队,对β-半乳糖苷酶(beta-galactosidase)及其抑制子PETG(phenylethy

张令强:泛素化研究将为药物研发和疾病治疗提供更多靶标

蛋白质是包括人类在内各种生物体的重要组成成分。对于生物体而言,蛋白质的生老病死至关重要,然而,科学家关于蛋白质如何"诞生"的研究成果很多,但关于蛋白质如何"死亡"的研究却相对较少。直到20世纪70-80年代,泛素调节的蛋白质降解机理被揭示,指明了蛋白质降解研究的方向,这一研究在2004年被授予诺贝尔化学奖,充分体现了泛素化修饰的研究价值。 本次生物谷有幸邀请了国内泛素化研究领域的专家张令强教

Moderna再获4亿5千万风投剑指mRNA药物研发

最近总部位于美国麻省坎布里奇市的生物技术公司Moderna公司宣布再获四亿五千万美元风投资金。这也是公司自成立以来所获得的最大规模的投资。 本轮投资的主要投资方包括Viking Global Investors、Invus、RA Capital Management和Wellington Management等著名风投公司。而Moderna公司的投资方兼研究伙伴阿斯利康公司和Alexion公司也

Google如何用机器学习帮助药物研发?

从在搜索中回答与健康相关的问题,到给开发者提供健身数据平台,Google在我们的日常健康中越来越重要。但其实互联网巨头们也在努力加快研发治愈人类顽疾的关键药物。 同斯坦福大学的Pande Lab合作,Google Research发表了一篇题为“针对药物研发的大规模多任务网络”的文章。该文章描述了如何用不同来源的数据,更好地确定哪种化合物将作为“治疗多种顽疾的有效药物”。 文章本身并没有显示任

"没事走两步" 美国拟要求将药物研发临床数据信息上网公布

一直以来,每个生物医药公司都十分重视本公司的临床研究数据保密,除了提交FDA审核以及必要的信息披露。很少见到生物医药公司主动将研究的细节公之于众。此外,医药公司一般都会倾向于公布获得成功的研究数据,颇有报喜不报忧的嫌疑。最近美国卫生部联手美国国家健康研究中心正在考虑推行一项措施要求医药研发企业让必要的临床研发数据公布在指定网站上。不过NIH指出这一措施不包括临床一期研究和可行性研究。研发机构不需要

Immunity:一种人体蛋白质有助清除结核杆菌

日本九州大学的一个研究小组近日在美国《免疫》杂志网络版上报告说,他们发现人体免疫细胞中的一种蛋白质,能有助于免疫细胞清除结核杆菌。这一发现有望促进结核病治疗药物研发。 这种蛋白质名为Dectin-2,位于人体免疫细胞内,具有与糖结合的特性。九州大学生物调控医学研究所教授山崎晶领导的研究小组发现,Dectin-2能识别结核杆菌中最具特征的一种糖脂——脂阿拉伯甘露聚糖,并由此激活免疫细胞,进而清

Baidu
map
Baidu
map
Baidu
map